Download pdf - IFRS Financial Statements 2014 - Investors Biocartis

Transcript
Page 1: IFRS Financial Statements 2014 - Investors Biocartis

IFRS Financial Statements 2014

Page 2: IFRS Financial Statements 2014 - Investors Biocartis
Page 3: IFRS Financial Statements 2014 - Investors Biocartis
Page 4: IFRS Financial Statements 2014 - Investors Biocartis
Page 5: IFRS Financial Statements 2014 - Investors Biocartis
Page 6: IFRS Financial Statements 2014 - Investors Biocartis
Page 7: IFRS Financial Statements 2014 - Investors Biocartis
Page 8: IFRS Financial Statements 2014 - Investors Biocartis
Page 9: IFRS Financial Statements 2014 - Investors Biocartis
Page 10: IFRS Financial Statements 2014 - Investors Biocartis
Page 11: IFRS Financial Statements 2014 - Investors Biocartis
Page 12: IFRS Financial Statements 2014 - Investors Biocartis
Page 13: IFRS Financial Statements 2014 - Investors Biocartis
Page 14: IFRS Financial Statements 2014 - Investors Biocartis
Page 15: IFRS Financial Statements 2014 - Investors Biocartis
Page 16: IFRS Financial Statements 2014 - Investors Biocartis
Page 17: IFRS Financial Statements 2014 - Investors Biocartis
Page 18: IFRS Financial Statements 2014 - Investors Biocartis
Page 19: IFRS Financial Statements 2014 - Investors Biocartis
Page 20: IFRS Financial Statements 2014 - Investors Biocartis
Page 21: IFRS Financial Statements 2014 - Investors Biocartis
Page 22: IFRS Financial Statements 2014 - Investors Biocartis
Page 23: IFRS Financial Statements 2014 - Investors Biocartis
Page 24: IFRS Financial Statements 2014 - Investors Biocartis
Page 25: IFRS Financial Statements 2014 - Investors Biocartis
Page 26: IFRS Financial Statements 2014 - Investors Biocartis
Page 27: IFRS Financial Statements 2014 - Investors Biocartis
Page 28: IFRS Financial Statements 2014 - Investors Biocartis
Page 29: IFRS Financial Statements 2014 - Investors Biocartis
Page 30: IFRS Financial Statements 2014 - Investors Biocartis
Page 31: IFRS Financial Statements 2014 - Investors Biocartis
Page 32: IFRS Financial Statements 2014 - Investors Biocartis
Page 33: IFRS Financial Statements 2014 - Investors Biocartis
Page 34: IFRS Financial Statements 2014 - Investors Biocartis
Page 35: IFRS Financial Statements 2014 - Investors Biocartis
Page 36: IFRS Financial Statements 2014 - Investors Biocartis
Page 37: IFRS Financial Statements 2014 - Investors Biocartis
Page 38: IFRS Financial Statements 2014 - Investors Biocartis
Page 39: IFRS Financial Statements 2014 - Investors Biocartis
Page 40: IFRS Financial Statements 2014 - Investors Biocartis
Page 41: IFRS Financial Statements 2014 - Investors Biocartis
Page 42: IFRS Financial Statements 2014 - Investors Biocartis
Page 43: IFRS Financial Statements 2014 - Investors Biocartis
Page 44: IFRS Financial Statements 2014 - Investors Biocartis
Page 45: IFRS Financial Statements 2014 - Investors Biocartis
Page 46: IFRS Financial Statements 2014 - Investors Biocartis
Page 47: IFRS Financial Statements 2014 - Investors Biocartis
Page 48: IFRS Financial Statements 2014 - Investors Biocartis
Page 49: IFRS Financial Statements 2014 - Investors Biocartis
Page 50: IFRS Financial Statements 2014 - Investors Biocartis
Page 51: IFRS Financial Statements 2014 - Investors Biocartis
Page 52: IFRS Financial Statements 2014 - Investors Biocartis
Page 53: IFRS Financial Statements 2014 - Investors Biocartis
Page 54: IFRS Financial Statements 2014 - Investors Biocartis

Recommended

GAZPROM: 2017 IFRS RESULTS...2017 IFRS RESULTS DISCLAIMERS This presentation has been prepared by PJSC Gazprom (the “Company”), and comprises the slides for a presentation to investors
GAZPROM: 2017 IFRS RESULTS...2017 IFRS RESULTS DISCLAIMERS This presentation has been prepared by PJSC Gazprom (the “Company”), and comprises the slides for a presentation to investors Documents
Presentation to Investors - AvivaSA · 2018. 11. 20. · 6 Summary of P&L from IFRS Segmental Reporting Source: Company information, IFRS and segmental reporting. 2013 2014 2015 (restated)
Presentation to Investors - AvivaSA · 2018. 11. 20. · 6 Summary of P&L from IFRS Segmental Reporting Source: Company information, IFRS and segmental reporting. 2013 2014 2015 (restated) Documents
ROS AGRO PLC INVESTORS PRESENTATION · ROS AGRO PLC INVESTORS PRESENTATION 14 AUGUST 2020 2Q AND 6M 2020. TABLE OF CONTENTS 2 2 3 2 Summary Key Indicators (IFRS) 2Q and 6M 2020 vs
ROS AGRO PLC INVESTORS PRESENTATION · ROS AGRO PLC INVESTORS PRESENTATION 14 AUGUST 2020 2Q AND 6M 2020. TABLE OF CONTENTS 2 2 3 2 Summary Key Indicators (IFRS) 2Q and 6M 2020 vs Documents
IFRS 9 Analytical and Reporting Solutions for · IdIoSyNCRA tIC RISk CHARACtERIStICS oF ... This would provide investors with the opportunity to apply ... 6 IFRS 9 AnAlytIcAl And
IFRS 9 Analytical and Reporting Solutions for · IdIoSyNCRA tIC RISk CHARACtERIStICS oF ... This would provide investors with the opportunity to apply ... 6 IFRS 9 AnAlytIcAl And Documents
PERFORMANCE 2020 - Investors Biocartis
PERFORMANCE 2020 - Investors Biocartis Documents
Biocartis Corporate presentation
Biocartis Corporate presentation Documents
Biocartis Corporate presentation · 2021. 1. 11. · 2 This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form
Biocartis Corporate presentation · 2021. 1. 11. · 2 This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form Documents
IFRS 16 - LEASES: IMPLICATIONS FOR ANALYSTS AND INVESTORS · (IASB, 2016). Under IFRS 16, the substantially different accountancy treatment of operating leases and finance leases
IFRS 16 - LEASES: IMPLICATIONS FOR ANALYSTS AND INVESTORS · (IASB, 2016). Under IFRS 16, the substantially different accountancy treatment of operating leases and finance leases Documents
BIOCARTIS ANNOUNCES 2016 RESULTS, 2017 OUTLOOK AND …€¦ · BIOCARTIS ANNOUNCES 2016 RESULTS, 2017 OUTLOOK AND CHANGE IN CEO POSITION Mechelen, Belgium, 2 ... Biocartis and Merck
BIOCARTIS ANNOUNCES 2016 RESULTS, 2017 OUTLOOK AND …€¦ · BIOCARTIS ANNOUNCES 2016 RESULTS, 2017 OUTLOOK AND CHANGE IN CEO POSITION Mechelen, Belgium, 2 ... Biocartis and Merck Documents
Investors(75)june2008 aaoifi-vs-ifrs-mohammad-majd-bakir
Investors(75)june2008 aaoifi-vs-ifrs-mohammad-majd-bakir Economy & Finance
Transition IFRS 9 and IFRS 17 Interaction - … · IAS 39 & IFRS 4 IFRS 9 & IFRS 4 IFRS 9 & IFRS 17 Deferral approach Overlay approach IFRS 9 and IFRS 17 Timeline. 7 • The objective
Transition IFRS 9 and IFRS 17 Interaction - … · IAS 39 & IFRS 4 IFRS 9 & IFRS 4 IFRS 9 & IFRS 17 Deferral approach Overlay approach IFRS 9 and IFRS 17 Timeline. 7 • The objective Documents
Biocartis Corporate presentation · 2020-03-04 · This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part
Biocartis Corporate presentation · 2020-03-04 · This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part Documents
Группа ПАО «БАНК «САНКТ ПЕТЕРБУРГ ... › investors › financial-statements › IFRS › ... · Аудируемое лицо: ПАО «Банк «Санкт-Петербург»
Группа ПАО «БАНК «САНКТ ПЕТЕРБУРГ ... › investors › financial-statements › IFRS › ... · Аудируемое лицо: ПАО «Банк «Санкт-Петербург» Documents
IFRS Foundation Annual Report 2015 · • IFRS Standards bring transparency by enhancing the international comparability and quality of financial information, enabling investors and
IFRS Foundation Annual Report 2015 · • IFRS Standards bring transparency by enhancing the international comparability and quality of financial information, enabling investors and Documents
CLOSING THE GAP ˜ ˜ IDYLLA™ GENEFUSION - Biocartis · 2021. 1. 15. · Biocartis NV Generaal de Wittelaan 11B 2800 Mechelen - Belgium +32 15 632 888 customerservice@biocartis.com
CLOSING THE GAP ˜ ˜ IDYLLA™ GENEFUSION - Biocartis · 2021. 1. 15. · Biocartis NV Generaal de Wittelaan 11B 2800 Mechelen - Belgium +32 15 632 888 [email protected] Documents
IFRS Standards and long-term investments · Long-term investors in an entity: concerns of some commentators “Information needs of long-term investors in an entity may differ from
IFRS Standards and long-term investments · Long-term investors in an entity: concerns of some commentators “Information needs of long-term investors in an entity may differ from Documents
2011 9 30 - EY Japan€¦ · 15 ifrs ifrs for smes ifrs ifrs ifrs iasb 1 ifrs. ifrs. iasc. iascf iasb ifrs ifrs iasb. ifrs. 2011. 9. 30 ifrs ifrs. ias 8. ifrs. ifrs ifrs ifrs. ifrs
2011 9 30 - EY Japan€¦ · 15 ifrs ifrs for smes ifrs ifrs ifrs iasb 1 ifrs. ifrs. iasc. iascf iasb ifrs ifrs iasb. ifrs. 2011. 9. 30 ifrs ifrs. ias 8. ifrs. ifrs ifrs ifrs. ifrs Documents
2015 Results Presentation - Investors Biocartis · 2019. 10. 21. · 1. Source: Markets & Markets: In Vitro Diagnostics (IVD) Market by Product Technology (Immunoassay, Clinical Chemistry,
2015 Results Presentation - Investors Biocartis · 2019. 10. 21. · 1. Source: Markets & Markets: In Vitro Diagnostics (IVD) Market by Product Technology (Immunoassay, Clinical Chemistry, Documents